Printer Friendly

DEPRENYL USA COMMENCES INITIAL CONTROLLED HUMAN CLINICAL TRIALS

 PARSIPPANY, N.J., March 4 /PRNewswire/ -- Deprenyl USA, Inc. (NASDAQ: DUSA) reports that Phase I/IIA human clinical trials for ALA Photodynamic Therapy (PDT) commenced the week of Feb. 21 at the University of California, Irvine. The principal investigator is Dr. Gerald Weinstein, head of the Department of Dermatology at the university. The University of California, Irvine, is a renowned center for the investigation of advanced dermatology treatment techniques, such as photodynamic therapy.
 Three separate human trials are involved, totalling more than 100 patients. The purpose of the research is to determine the clinically effective dosages of drug and light required to treat actinic keratoses and psoriasis. These studies involve a variety of protocols contained in the company's Investigational New Drug (IND) submission to the FDA which became effective in January 1993.
 Deprenyl USA is a development stage company established to bring prescription pharmaceutical products to worldwide markets, initially in the United States and Canada and primarily in the field of photodynamic therapy.
 Common stock and warrants are traded on NASDAQ under the symbols DUSA and DUSAW. They also trade on the Toronto Stock Exchange under the symbols DPU and DPU.WT.
 -0- 3/4/93
 /CONTACT: Toronto Office: Geoffrey Shulman, MD, president & CEO, 416-537-1070, or fax, 416-537-0258; Joseph P. Castelli, vice president, 201-299-9070, or fax, 201-335-0372, both of Deprenyl USA; Jim Tolan, sr. vice president, or Nicholas Biro, partner, 708-498-2284, or fax, 708-498-3144, both of O'Connor Biro & Associates, for Deprenyl USA/
 (DUSA)


CO: Deprenyl USA, Inc. ST: New Jersey IN: MTC SU:

LR -- NY024 -- 2845 03/04/93 09:31 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 4, 1993
Words:262
Previous Article:MAYOR DINKINS ANNOUNCES INTERACTIVE TV LEARNING NETWORK THAT LINKS THREE PUBLIC HIGH SCHOOLS AND A CUNY COMMUNITY COLLEGE
Next Article:ROWAN COMPANIES CHAIRMAN PREDICTS FUTURE BUSINESS CONDITIONS
Topics:


Related Articles
PROTEIN DESIGN LABS ISSUES INTERIM REPORT ON CLINICAL TRIALS
LUNAR ANNOUNCES THAT ONE-ALPHA D2 WAS EFFECTIVE
DEPRENYL USA COMMENCES INITIAL CONTROLLED HUMAN CLINICAL TRIALS
DEPRENYL USA REPORTS YEAR END 1992 RESULTS; CONFIRMS ALA PHOTODYNAMIC DEVELOPMENT ON SCHEDULE; PROPOSES NAME CHANGE TO DUSA PHARMACEUTICALS
DEPRENYL USA'S EXPERIMENTAL DRUG HAS POTENTIAL AS 'TREATMENT OF CHOICE' FOR SKIN CANCERS, SAYS PRESIDENT; NAME CHANGED TO DUSA PHARMACEUTICALS
VERTEX BEGINS PHASE II CLINICAL TRIAL WITH VX-105 TO TREAT HEMOGLOBIN DISORDERS
DEPRENYL ANIMAL HEALTH LAUNCHES PIVOTAL CLINICAL TRIAL FOR USE OF L-DEPRENYL IN TREATING COGNITIVE DYSFUNCTION
ALEXION INITIATES FIRST OF C5 INHIBITOR CLINICAL TRIALS
LXR Biotechnology Inc. Receives FDA Permission to Commence Pivotal Clinical Trial for Heart Preservation Solution(z)
CYTRX CLINICAL TRIAL OF ARIMOCLOMOL FOR ALS SHOWS PROMISE.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters